Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program
Sangamo launched an auction process for ST-503, its clinical-stage epigenetic regulator for chronic neuropathic pain, with completion expected in the fourth quarter of 2026. The company confirmed that its court-supervised Section 363 asset sales to PTC Therapeutics and Eli Lilly have closed, generating $163.55 million in gross cash proceeds, and it repaid its DIP financing from Future Solutions in full.
Key figures
- Deal Value Usd
- 163550000
- Dip financing
- repaid in full
- Sfn us prevalence
- 180000
- Ptc fabry deal cash
- $111 million
- Lilly platforms deal
- $50 million
- Ptc fabry milestones
- $100 million
- Peripheral neuropathy us prevalence
- 40 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.